Back

Comparison of the sensitivity of commercial aPTT tests in measurement of the pharmacodynamic response of milvexian, a novel FXIa inhibitor

27 August 2021 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Pharmacology and pharmacotherapy e-posters Anticoagulants ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Ms Fany Bonilla

Spring House (United States of America)

57 More presentations in this session

Presentation thumbnail
Efficacy of propafenone vs. amiodarone in pharmacological cardioversion of recent-onset atrial fibrillation to sinus rhythm: a pooled meta-analysis of 9 randomized controlled trials
Doctor J. Borovac (Split, HR)
Abstract Slides
Presentation thumbnail
The prevalence and safety of direct oral anticoagulants in patients with non-atrial fibrillation associated intra-cardiac thrombus
Doctor A. KANWAL (Valhalla, US)
Abstract Slides
Presentation thumbnail
Efficiency and safety of the modified protocol for cardioversion of atrial fibrillation using the antiarrhythmic drug niferidil. First results of clinical use.
Doctor K. Dzaurova (Moscow, RU)
Abstract Slides
Presentation thumbnail
The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a meta-analysis
Mrs A. Boulmpou (Nijmegen, NL)
Abstract Slides
Presentation thumbnail
Risk of death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials: an updated meta-analysis
Mrs A. Boulmpou (Nijmegen, NL)
Abstract Slides

Access the full session

Session thumbnail
Pharmacology and pharmacotherapy e-posters

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Anti-Xa/APTT discrepancy in heparinized ImpellaTM-supported cardiogenic shock patients can predict mortality
9 March 2024
thumbnail
Congress Presentation
The complete bioavailability of asundexian is unaffected by tablet formulation, gastric pH or food
29 August 2022
thumbnail
Congress Presentation
Inhibition of Factor XI using a GalNAc-siRNA RBD5049: a novel antithrombotic drug with high potency and long duration
28 August 2023
thumbnail
Congress Presentation
Prior anticoagulation experience, bleeding risk, and safety of factor XI inhibition in atrial fibrillation: an analysis of AZALEA-TIMI 71
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources